US009511125B2

(12) **United States Patent**
Fallon et al.

(10) **Patent No.: US 9,511,125 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) **METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA**

(75) Inventors: **Joan M. Fallon**, Bronxville, NY (US); **Matthew F. Heil**, Sherman, CT (US); **James J. Fallon**, Armonk, NY (US); **James Szigethy**, Montgomery, NY (US)

(73) Assignee: **CUREMARK LLC**, Rye, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/502,989**

(22) PCT Filed: **Oct. 21, 2010**

(86) PCT No.: **PCT/US2010/053484**

§ 371 (c)(1),
(2), (4) Date: **Jun. 28, 2012**

(87) PCT Pub. No.: **WO2011/050135**

PCT Pub. Date: **Apr. 28, 2011**

(65) **Prior Publication Data**

US 2012/0258149 A1 Oct. 11, 2012

Related U.S. Application Data

(60) Provisional application No. 61/253,805, filed on Oct. 21, 2009.

(51) **Int. Cl.**

A61K 38/43	(2006.01)
A61K 9/28	(2006.01)
A61K 38/46	(2006.01)
A61K 38/48	(2006.01)
A61K 9/00	(2006.01)
A61K 38/47	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/465*** (2013.01); ***A61K 9/0014*** (2013.01); ***A61K 38/47*** (2013.01); ***A61K 38/4826*** (2013.01); ***A61K 38/4873*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/00; A61K 38/465; A61K 38/48; A61K 9/20; A61K 9/48; A61K 35/39; A61K 35/37; C12N 9/00; C12N 9/50; C12N 9/64; C12N 9/6421; C12N 9/94; C12Y 304/00; C12Q 1/00; C12Q 1/70

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,002,883	A	10/1961	Butt et al.
3,223,594	A	12/1965	Serge
3,322,626	A	5/1967	D'Argento
3,357,894	A	12/1967	Jose et al.
3,515,642	A	6/1970	Mima et al.
3,574,819	A	4/1971	Gross et al.
3,860,708	A	1/1975	Prout
3,940,478	A	2/1976	Kurtz
4,079,125	A	3/1978	Sipos
4,145,410	A	3/1979	Sears
4,241,046	A	12/1980	Papahadjopoulos et al.
4,280,971	A	7/1981	Wischniewski et al.
4,447,412	A	5/1984	Bilton
4,456,544	A	6/1984	Lupova et al.
4,623,624	A	11/1986	Schultze
4,826,679	A	5/1989	Roy
5,190,775	A	3/1993	Klose
5,250,418	A	10/1993	Moller et al.
5,324,514	A	6/1994	Sipos
5,378,462	A	1/1995	Boedecker et al.
5,436,319	A	7/1995	Kung et al.
5,437,319	A	8/1995	Garuglieri
5,439,935	A	8/1995	Rawlings et al.
5,460,812	A	10/1995	Sipos
5,476,661	A	12/1995	Pillai et al.
5,527,678	A	6/1996	Blaser et al.
5,585,115	A	12/1996	Sherwood et al.
5,607,863	A	3/1997	Chandler
5,648,335	A	7/1997	Lewis et al.
5,674,532	A	10/1997	Atzl et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2198317	A1	2/1997
CA	2263703	A1	8/1999

(Continued)

OTHER PUBLICATIONS

Roxas, M. et al. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Alternative Medicine Review (2007) 12(1):25-48; p. 27.*

Millipore EMD catalog (online), Papain, Unit definition, EMD Millipore Corp. 2013, downloaded May 13, 2013. p. 1.*

King, M.D. et al. 2011. Effects of Bacterial Microflora of the Lower Digestive Tract of Free-Range Waterfowl on Influenza Virus Activation. Applied and Environmental Microbiology 77(12):4119-4125. specif. pp. 4119, 4121, 4124.*

Cichoke, a.J. Influenza. In: The Complete Book of Enzyme Therapy. D. Stewart, ed. Copyright 1999. Anthony J. Cichoke. Penguin Putnam, Inc., New York, New York. pp. "Contents", 50, 273-275 and 455.*

American Laboratories Inc. Pancreatin 8X USP Powder. Product Specification. Jul. 2000. In: Product Manual. American Laboratories Incorporated. Omaha, NE. p. 1.*

(Continued)

Primary Examiner — Renee Claytor
Assistant Examiner — Sharon M Papciak
(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

A method to treat Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes, is disclosed. The method includes the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.

20 Claims, No Drawings